Person:
KIYICI, MURAT

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KIYICI

First Name

MURAT

Name

Filters

20215
Reset filters

Settings

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Publication
    Covid-19 in liver transplant recipients: A national cohort
    (Elsevier, 2021-07-01) Kabaçam, Gökhan; Turan, İlker; Kiyici, Murat; Ellik, Zeynep Melekoğlu; Dolu, Süleyman; Dayanğaç, Murat; Arı, Derya; Gökçe, Dilara Turan; Yıldırım, Abdullah Emre; Gençdal, Genco; Harputluoğlu, Murat; Kartal, Aysun; Demiray, Emine Kübra Dindar; Gündüz, Feyza; Ergenç, İlkay; Efe, Cumali; Sümer, Hale Gökcan; Kayhan, Meral Akdoğan; Gülşen, Murat Taner; Akyıldız, Murat; Arıkan, Çiğdem; Karademir, Sedat; Balcı, Deniz; Dündar, Ziya; Akarsu, Mesut; Günşar, Fulya; Karasu, Zeki; İdilman, Ramazan; KIYICI, MURAT; DÜNDAR, HALİT ZİYA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; FHW-0015-2022; JHK-0911-2023
  • No Thumbnail Available
    Publication
    Efficacy and safety of tenofovir alafenamide in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation: A preliminary result
    (Lippincott Williams & Wilkins, 2021-10-01) Adanır, Haydar; Etik, Diğdem Özer; Yıldırım, Abdullah Emre; Mehdiyev, Shahin; Yapalı, Suna; Coşar, Arif Mansur; Arı, Derya; Gökcan, Hale; Teker, Tufan; Kıyıcı, Murat; Balaban, Yasemin Hatice; Alkım, Hüseyin; Üçbilek, Enver; Ünsal, Yasemin; Harputluoğlu, Murat; Vatansever, Sezgin; Demir, Mehmet; Güzelbulut, Fatih; Gündüz, Feyza; Boyacıoğlu, Sedat; Bilgiç, Yılmaz; Ekmen, Nergis; Arslan, Mehmet; Şimşek, Halis; Akdoğan, Meral; Dinçer, Dinç; Tozun, Nurdan; İdilman, Ramazan; TEKER, TUFAN; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; EAB-6931-2022; FHW-0015-2022
  • Thumbnail Image
    Publication
    Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis
    (Wiley, 2021-11-28) Efe, Cumali; Lammert, Craig; Taşcılar, Koray; Dhanasekaran, Renumathy; Ebik, Berat; Higuera-de la Tijera, Fatima; Çalışkan, Ali R.; Peralta, Mirta; Gerussi, Alessio; Massoumi, Hatef; Catana, Andreea M.; Purnak, Tuğrul; Rigamonti, Cristina; Aldana, Andres J. G.; Khakoo, Nidah; Nazal, Leyla; Frager, Shalom; Demir, Nurhan; Irak, Kader; Melekoğlu-Ellik, Zeynep; Kaçmaz, Hüseyin; Balaban, Yasemin; Atay, Kadri; Eren, Fatih; Alvares-da-Silva, Mario R.; Cristoferi, Laura; Urzua, Alvaro; Eskazan, Tuğçe; Magro, Bianca; Snijders, Romee; Barutcu, Sezgin; Lytvyak, Ellina; Zazueta, Godolfino M.; Demirezer-Bolat, Aylin; Aydın, Mesut; Heurgue-Berlot, Alexandra; De Martin, Eleonora; Ekin, Nazım; Yıldırım, Sümeyra; Yavuz, Ahmet; Bıyık, Murat; Narro, Graciela C.; Kıyıcı, Murat; Akyıldız, Murat; Kahramanoğlu-Aksoy, Evrim; Vincent, Maria; Carr, Rotonya M.; Günşar, Fulya; Reyes, Eira C.; Harputluoğlu, Murat; Aloman, Costica; Gatselis, Nikolaos K.; Ustundağ, Yücel; Brahm, Javier; Vargas, Nataly C. E.; Güzelbulut, Fatih; Garcia, Sandro R.; Aguirre, Jonathan; Anders, Margarita; Ratusnu, Natalia; Hatemi, İbrahim; Mendizabal, Manuel; Floreani, Annarosa; Fagiuoli, Stefano; Silva, Marcelo; Idılman, Ramazan; Satapathy, Sanjaya K.; Silveira, Marina; Drenth, Joost P. H.; Dalekos, George N.; Assis, David N.; Bjornsson, Einar; Boyer, James L.; Yoshida, Eric M.; Invernizzi, Pietro; Levy, Cynthia; Montano-Loza, Aldo J.; Schiano, Thomas D.; Ridruejo, Ezequiel; Wahlin, Staffan; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; FHW-0015-2022
    Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.
  • No Thumbnail Available
    Publication
    Real life efficacy and tolerability of tenofovir alafenamide fumarate in patients with hepatitis B virus-related cirrhosis and liver transplant recipients. A-preliminary result
    (Wiley, 2021-10-01) Yapalı, Suna; Gökcan, Hale; Harputluoğlu, Murat; Ellik, Zeynep Melekoğlu; Akarsu, Mesut; Durak, Serdar; Gökçen, Pınar; Adanır, Haydar; Arı, Derya; Mehdiyev, Shahin; Vatansever, Sezgin; Güzelbulut, Fatih; Teker, Tufan; Alkım, Hüseyin; Bilgiç, Yılmaz; Arslan, Mehmet; Özdil, Kamil; Koç, Elif Sitre; Etik, Diğdem Özer; Yıldırım, Emre; Balaban, Yasemin Hatice; Gündüz, Feyza; Kıyıcı, Murat; Akdoğan, Meral; Boyacıoğlu, Sedat; Ekmen, Nergis; Tozun, Nurdan; Şimşek, Halis; Dinçer, Dinç; Idılman, Ramazan; TEKER, TUFAN; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; EAB-6931-2022 ; FHW-0015-2022
  • Thumbnail Image
    Publication
    Recommendations for hepatitis B immunoglobulin and antiviral prophylaxis against hepatitis B recurrence after liver transplantation
    (Aves, 2021-08-31) Akarsu, Mesut; Önem, Soner; Turan, İlker; Adalı, Gupse; Akdoğan, Meral; Akyıldız, Murat; Aladağ, Murat; Balaban, Yasemin; Danış, Nilay; Dayangaç, Murat; Gençdal, Genco; Gökcan, Hale; Sertesen, Elif; Gürakar, Merve; Harputluoğlu, Murat; Kabacam, Gökhan; Karademir, Sedat; Kıyıcı, Murat; Idılman, Ramazan; Karasu, Zeki; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 0000-0002-3208-6211; FHW-0015-2022
    The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.